Midi vs Alloy

For insured patients, Midi Health is cheaper: Midi is in-network with most major US health plans (Aetna, BCBS, Cigna, United, Medicare in many states) and visits typically run a $0–$50 copay. For cash-pay patients, Alloy is more predictable — its flat monthly subscription starts at $49 and includes the clinician visit, prescriptions written, and medication shipping. Without HRT-friendly insurance, Alloy’s all-in price usually beats Midi’s cash rate of approximately $99 per visit.

Both clinical teams are anchored on Menopause Society Certified Practitioners (MSCP). Alloy publishes its medical advisory board publicly, including a board of MSCP-certified physicians. Midi publishes its clinical leadership (Chief Medical Officer Dr. Kathleen Jordan) and credentials clinicians through The Menopause Society. At the individual provider level they are comparable; both meet the credential floor described in the 2022 Menopause Society Hormone Therapy Position Statement (Menopause 29(7):767–794).

Yes. Both services prescribe off-label transdermal testosterone in physiologic female doses for postmenopausal hypoactive sexual desire disorder (HSDD), consistent with the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women (J Clin Endocrinol Metab 104(10):4660–4666). There is no FDA-approved testosterone product for women in the US as of 2026. Neither service prescribes compounded pellet testosterone, which the global consensus statement explicitly recommends against.

Both services prescribe FDA-approved bioidentical hormones — estradiol patches and gels, oral micronized progesterone (Prometrium), and vaginal estradiol — which are mass-manufactured to defined potency. Neither defaults to compounded bioidentical hormones, which the 2020 National Academies of Sciences consensus report concluded should not be routinely used because they are not FDA-tested for safety, efficacy, or batch consistency.

Neither service is the right fit for complex cases — both are telehealth-only and do not perform pelvic exams, imaging, or in-person workups. For a personal or first-degree-relative history of breast cancer, prior venous thromboembolism, undiagnosed abnormal uterine bleeding, a previously failed HRT trial, or care that must coordinate with oncology or endocrinology, see a local MSCP-credentialed physician (use this directory’s state pages). This matches the contraindication list in the 2022 Menopause Society Hormone Therapy Position Statement.

Yes. As of May 2026, both Midi Health and Alloy operate in all 50 US states. State availability is verified against each service’s public pricing/coverage page on the retrieval date shown in the sources block.